Supplementary Information

Supplementary Figures
VISTA is expressed in patient samples A) Related to Figures 1 and 2, shown is the gating strategy. Cells were gated for live cells and CD45 positivity was used to select for immune cells. To select for melanoma cells, the CD45 negative population was additionally gated for positive staining of a melanoma antibody cocktail against GP100, Melan-A, and S100. B) VISTA gating was determined by comparing fluorescence levels to negative controls and by assessing the separation of positive and negative populations across the whole sample and within individual cell subsets. Once a gate was determined, it was applied to all cell subsets within the same sample. Shown is a representative gate of all Live Cells analyzed for VISTA staining. C-F) A tissue microarray of melanoma patient samples was stained for VISTA by immunohistochemistry. The number of VISTA-positive tumor cells was determined for each sample by a pathologist and the number of large, round nuclei was determined by Visiopharm. Each score value was divided by the number of nuclei in that sample, and log-transformed (-log10(score)). Shown are box plots average scores for all expressing (non-zero) patient samples comparing across C) Tumor Type D) Mutation Status E) Stage and F) Sex. Scores from patients with multiple samples were averaged. Patients with no listed mutation status were omitted from graph D. The dark line in each box plot represents the median of the scores for that group, and the circles represent outliers. Significance was tested using a non-parametric Mann-Whitney U Test. All graphs were created using IBM® SPSS software (v25). G) Cell lysates were generated from primary cultures of keratinocytes, melanocytes, and fibroblasts, and from immortalized fibroblasts (HTERT).
Primary cultures of cancer-associated fibroblasts (CAFs) from different patients (each patient indicated by a different #) were characterized by expression or upregulation of ⍺-SMA, PDGFR⍺ or FAP and lack of SOX10 or BRAF V600E and cell lysates were generated. VISTA expression was probed by Western blot. Lysates from siRNA knockdown of VISTA or a non-targeting control in 1205Lu cells were used as controls for each blot.
Supplementary Figure 2, Related to Figures 2 and 3: VISTA is N-linked glycosylated in melanoma cell lines, and has minor effects on wound closure and growth
A) Cells were treated with varying concentrations of the N-linked glycosylation inhibitor tunicamycin for 24 hours. Cell lysates were analyzed by western blot. B) Cells were transfected with two different siRNAs targeting VISTA or a non-targeting control for 72 hours. Cells were treated with or without 0.1μg/mL tunicamycin for an additional 24 hours, then lysates were probed by western blot. C) siRNA transfection was utilized to knockdown VISTA. 24 hours post transfection, cells were plated onto agarose to form spheroids. Cells were allowed to form spheroids for 4 days, then placed into 3D collagen matrix and incubated for an additional 2 days. Cells were incubated with calcein to mark live cells, and images were taken. The area of the invasive front was quantified using ImageJ and normalized to the area of the spheroid. D-E) siRNA transfection was utilized to knockdown VISTA. 72 hours post transfection, cells were plated onto a 96-well plate. The Incucyte ® WoundMaker TM was utilized to create a uniform scratch across all wells. Cells were imaged by the Essen Incucyte ® Zoom Live cell imager and relative wound density was quantified as percentage confluence within the original scratch. F-G) siRNA transfection was utilized to knockdown VISTA. 72 hours post transfection, cells were replated and imaged by the Essen Incucyte ® Zoom Live cell imager and cell growth was quantified as percent plate confluence. tumor samples were stained with fluorescent antibodies for flow cytometry analysis. Cells were gated for CD45 positivity to select for immune cells, and VISTA and PD-1 expression levels were determined. Cells were gated for CD45 negativity, then gated for S100/MELANA/GP100 positivity to select for melanoma cells, and VISTA and PD-L1 expression levels were determined. G) Cells were treated with 100ng/mL IFNγ for 48 hours, and lysates were probed by western blot. H) Cells were treated for 48 hours with 5ng/mL TGFβ1, 20ng/mL TNFα, 100ng/mL IL-6, 10ng/mL IL-1α, or 100ng/mL IFNγ, and lysates were probed by western blot. siRNA knockdown controls were transfected with VISTA targeting siRNA #1 or non-targeting control for 72 hours before lysis. 
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